EMEA-001501-PIP08-20

Key facts

Invented name
Dupixent
Active substance
dupilumab
Therapeutic area
Oto-rhino-laryngology
Decision number
P/0121/2021
PIP number
EMEA-001501-PIP08-20
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Treatment of chronic rhinosinusitis without nasal polyposis
Route(s) of administration
Subcutaneous use
Contact for public enquiries
sanofi-aventis recherche & développement

Tel. +33 1697 45695
E-mail: contact-us@sanofi.com

Decision type
W: decision granting a waiver in all age groups for all conditions or indications

Decision

Related content

How useful was this page?

Add your rating